Cancer-fighting MedTech eyes solvent voluntary liquidation
MedTechDeals The board of MedTech Achilles Therapeutics is proposing a members’ solvent voluntary liquidation. The London-headquartered firm, which has an office in Philadelphia and facilities at Stevenage Bioscience Catalyst, sold some of its technology assets to AstraZeneca late last year for $12m. Achilles, founded in 2016, was developing precision T cell therapies that target clonal…